MARKET ANALYSIS
Catheter-related bloodstream infections may occur due to bacteraemia at the tip of the catheter or between peripheral intravenous catheters. These catheter-related bloodstream infections are the most lethal, recurring, and cost-complex expenses because of high maintenance at the hospital for the infected patient. The cause of this is a multidrug-resistant pathogen acquired through invasive procedures, improper or uncontrolled use of antibiotics, and not following appropriate infection control practices called "nosocomial infections," also known as healthcare-associated infections. Intravascular and peripheral IV catheters are the cause of infection.
GROWTH DRIVERS AND CHALLENGES
Factors driving the catheter-related bloodstream infections (CRBSI) market growth are the increase in the occurrence of bloodstream infections, the rise in invasive medical procedures, and the growing adoption of advanced equipment. Invasive procedures often require the use of catheters, such as central venous catheters, urinary catheters, or dialysis catheters, which are inserted into the body for various purposes. Catheters also present a potential entry point for bacteria and other pathogens, leading to bloodstream infections. The rise in invasive medical procedures has had a direct impact on driving the catheter-related bloodstream infections market. The increased recognition of CRBSI risks and the need to improve patient outcomes have led to advancements in infection prevention strategies and the development of innovative products. The market continues to evolve as healthcare providers and manufacturers work together to reduce the incidence of CRBSIs and enhance patient safety in invasive procedures. Thus, the rise in the number of invasive medical procedures is fueling the catheter-related bloodstream infection market growth.
The absence of a surveillance system for infections associated with healthcare and these reasons often leads to problems in identifying such infections, as it is very challenging to set uniform diagnostic criteria. These are the key drivers and restraints of the catheter-related bloodstream infections market.
REPORT SEGMENTATION AND SCOPE
The "Global Catheter-related bloodstream infections Market Analysis to 2031" is a specialized and in-depth study with a major focus on the global catheter-related bloodstream infections market trends and growth opportunities. The report aims to provide an overview of the global catheter-related bloodstream infections market with detailed market segmentation by treatment type, source of infection, distribution channel, and geography. The global catheter-related bloodstream infections market has been witnessing high growth over the recent past and is expected to continue this trend during the forecast period. The report provides key statistics on the use of catheter-related bloodstream infections worldwide along with their demand in major regions and countries. In addition, the report provides the qualitative assessment of various factors affecting the catheter-related bloodstream infections market performance in major regions and countries. The report also includes a comprehensive analysis of the leading players in the catheter-related bloodstream infections market and their key strategic developments. Several analyses on the market dynamics are also included to help identify the key driving factors, market trends, and lucrative catheter-related bloodstream infections market opportunities that would, in turn, aid in identifying the major revenue pockets.
Further, ecosystem analysis and Porter's five forces analysis provide a 360-degree view of the global catheter-related bloodstream infections market. This helps understand the entire supply chain and various factors affecting the market growth.
SEGMENTAL ANALYSIS
The global catheter-related bloodstream infections market is segmented based on treatment type, source of infection, and distribution channel. Based on treatment type, the catheter-related bloodstream infections market is bifurcated into as anti-microbial agents and antibiotic lock therapy. On the basis of source of infection, the market is classified as coagulase-negative staphylococcus, s.aureus, enteric gram-negative bacilli, yeasts, enterococci & streptococci, pseudomonas, and others. The catheter-related bloodstream infections market is categorized based on distribution channel into hospital pharmacies, retail pharmacies, and online pharmacies.
Based on treatment type, the anti-microbial agents accounted for a significant catheter-related bloodstream infections market share which can be attributed to its popularity across the globe and wide availability. There are bloodstream infections caused by the presence of different types of antimicrobial agents that inhibit the colonization of catheters with pathogenic microbes and prevent CAUTIs (Catheter-associated urinary tract infections). The antimicrobial catheter, however, has several characteristics, e.g., its release of antimicrobials, changes in the surface of the catheter, contact killing, destruction of biofilm formation, and use of bacterial biofilms to prevent pathogen colonization. Despite these characteristics, urinary tract infections caused by antibacterial catheters are not decreasing. Therefore, antimicrobial catheters are predicted to have a higher market share in blood infections associated with catheters due to the reasons given above. Thus, the anti-microbial agents segment drives the growth of catheter-related bloodstream infections market share.
REGIONAL ANALYSIS
The report provides a detailed overview of the global catheter-related bloodstream infections market with respect to five major regions, namely, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. North America is estimated to account for a significant catheter-related bloodstream infections market share globally due to technological advances in blood-borne infection treatment and strong healthcare infrastructure, this trend is expected to prevail over the forecast period. Increasing numbers of American and Canadian patients with catheter blood infections, especially in the elderly, drive North America's market.
INDUSTRY DEVELOPMENTS AND FUTURE OPPORTUNITIES
Partnership, acquisitions and new product launches were found to be the major strategies adopted by the players operating in the global catheter-related bloodstream infections market.
In February 2021, CorMedix, Inc. announced that Neutrolin received grant from the U.S. Food and Drug Administration for the prevention of catheter-related blood stream infections (CRBSIs) in hemodialysis patients.
In April 2023, Citius Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, announced that it has advanced its clinical trial for Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections.
IMPACT OF COVID/IMPACT OF GEOPOLITICAL SCENARIO/IMPACT OF RECESSION
The COVID-19 pandemic significantly influenced the global market for catheter-related bloodstream infections. CRBSIs pose a higher risk due to increased demand for healthcare resources and strong pressure on healthcare systems. In addition, measures to control infections and increased use of catheters in COVID-19 patients reinforce the need for efficient prevention strategies. This analysis draws awareness to the impact of pandemics on the market and analyses how actions have been taken against CRBSI risks in these difficult times.
COMPETITIVE LANDSCAPE AND KEY COMPANIES
Some of the key players operating in the catheter-related bloodstream infections market include Merck Sharp & Dohme Corp, CorMedix, Inc., Geistlich Pharma AG, Pfizer, Glenmark Pharmaceuticals Ltd., Fresenius Medical Care, Taurophar GmbH, Citus Pharmaceuticals, AstraZeneca Pharma India Ltd., Xellia Pharmaceuticals Ltd. among others.
Catheter-related Bloodstream Infections Market Report Analysis
-
CAGR (2023 - 2031)XX% -
Market Size 2023
US$ XX Million -
Market Size 2031
US$ XX Million
Report Coverage
- Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Key future trends
- Detailed PEST/Porter’s Five Forces and SWOT analysis
- Industry landscape and competition analysis & recent developments
- Detailed company profiles
- Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
Key Players
- Merck Sharp and Dohme Corp
- CorMedix, Inc.
- Geistlich Pharma AG
- TauroPharm GmbH
- Fresenius Medical Care
- Pfizer
- Glenmark Pharmaceuticals Ltd.
- Citus Pharmaceuticals
- AstraZeneca Pharma India Ltd.
Regional Overview
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Market Segmentation
- Anti-microbial Agents
- Antibiotic Lock Therapy
- Coagulase-negative Staphylococcus
- S.aureus
- Enteric Gram-negative Bacilli
- Yeasts
- Enterococci and Streptococci
- Pseudomonas
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Catheter-related Bloodstream Infections Market Report Scope
Report Attribute | Details |
---|---|
Market size in 2023 | US$ XX Million |
Market Size by 2031 | US$ XX Million |
Global CAGR (2023 - 2031) | XX% |
Historical Data | 2021-2022 |
Forecast period | 2024-2031 |
Segments Covered |
By Treatment Type
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Trends and growth analysis reports related to Pharmaceuticals : READ MORE..
The List of Companies
1. Merck Sharp and Dohme Corp
2. CorMedix, Inc.
3. Geistlich Pharma AG
4. TauroPharm GmbH
5. Fresenius Medical Care
6. Pfizer
7. Glenmark Pharmaceuticals Ltd.
8. Citus Pharmaceuticals
9. AstraZeneca Pharma India Ltd.
10. Xellia Pharmaceuticals Ltd.